Enovis (NYSE:ENOV) Stock Rating Upgraded by Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other equities analysts have also issued reports on the company. BTIG Research raised their price target on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. UBS Group reiterated a “buy” rating and issued a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Finally, Wells Fargo & Company raised Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $47.43.

Enovis Stock Performance

Shares of Enovis stock opened at $22.74 on Monday. The firm’s fifty day simple moving average is $22.97 and its 200-day simple moving average is $27.05. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.10 and a beta of 1.46. Enovis has a 12 month low of $21.00 and a 12 month high of $38.56. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same quarter in the prior year, the business earned $0.98 EPS. Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis will post 2.79 earnings per share for the current year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert acquired 1,000 shares of the stock in a transaction on Friday, February 27th. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders purchased 5,000 shares of company stock valued at $121,983. 2.70% of the stock is currently owned by insiders.

Institutional Trading of Enovis

Hedge funds have recently modified their holdings of the business. Arax Advisory Partners acquired a new position in Enovis during the fourth quarter worth $29,000. Farther Finance Advisors LLC lifted its holdings in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Elevation Point Wealth Partners LLC purchased a new stake in shares of Enovis during the 2nd quarter worth $46,000. Finally, SJS Investment Consulting Inc. grew its stake in shares of Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after purchasing an additional 1,517 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.